To study lovastatin efficiency in NSCLC, Walther et al. found that lovastatin increases COX2 expression and subsequently activates PPAR-γ, which induces the cytotoxicity of lung cancer cells [98]. The gene discussed is PPARG; the disease is non-small cell lung carcinoma.